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Background: Patients with heart failure (HF) suffer from ventilatory abnormalities that are related to poor prognosis.  
Aim: The aim of the study was to investigate the respiratory drive in HF patients early after left ventricular assist device (LVAD) implan-
tation.  
Methods: We enrolled eight HF patients after LVAD (HeartMate II) implantation and 8 patients with advanced HF (control group). 
Patients were evaluated with cardiopulmonary exercise testing, respiratory function tests and transthoracic echocardiographic examina-
tion at 1, 3 and 6 months. Respiratory drive was estimated by the mouth occlusion pressure-P0.1 and the P0.1/Pimax ratio. 
Results: LVAD patients at 1, 3 and 6 months after implantation had significantly improved P0.1/Pimax% ratio (4.17±0.43 vs 3.29±1.0 vs 
2.56±0.35 respectively, p<0.01) as well as significantly increased in Pimax. No changes where observed in the HF control group. A signifi-
cant decrease in LVEDD, LVESD and an improvement in LVEF is also observed during follow up. 
Conclusions: Our results imply LVAD implantantion induces a progressive and significant improvement of respiratory drive and Left 
ventricle reverse remodeling during a 6 month follow-up period. 
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INTRODUCTION 
Despite modern optimal pharmacological management, pa-
tients with advanced heart failure (HF) experience severe exer-
cise intolerance mainly manifested by marked dyspnea and 
fatigue. 
HF patients present several respiratory derangements, includ-
ing restrictive and obstructive breathing pattern1 decreased 
lung compliance and hyperventilation.2 Respiratory muscle 
weakness3,4 and decreased inspiratory capacity5 have also been 
observed in these group of patients and are associated with 
exercise intolerance. Respiratory drive is significantly attenuat-
ed, indicating the exertion of a greater respiratory effort and is 
closely associated with dyspnoea,6 autonomic nervous system 
impairment, microcirculation dysfunction, exercise intolerance 
and disease severity,7,8 while it improves after interventions 
such as exercise training.9  
Long term mechanical support of the advanced failing heart 
utilizing left ventricular assist devices (LVAD) has become a 
standard bridge to transplantation and a destination therapy 
for selected patients with end-stage heart failure. Interestingly 
severe heart failure can be reversed in selected patients with 
the combination of LVAD and pharmacologic therapy (bridge 
to recovery).10  
We hypothesized that LVAD unloading, reversing the chronic 
stressor state, would induce beneficial effects in terms of myo-
cardial remodeling process and in the increased respiratory 
drive.  
We demonstrated previously a beneficial effect of LVAD im-
plementation on adversely affected parameters of respiratory 
function, in patients with advanced HF.11 In the present study 
we aimed to evaluate the effects of a continuous-flow LVAD on 
respiratory drive during a 6 month follow-up period after im-
plantation. 
 
MATERIAL AND METHODS 
Study population 
Our study design was a prospective observational study and 
the study population consisted of 8 consecutive patients with 
end-stage HF (6 males and 2 females, 44±19yrs, 22.9±2.4 
kg/m2, Left ventricular ejection fraction (LVEF): 21±3%, Left 
ventricular end-diastolic diameter (LVEDD): 68±7mm, Left ven-
tricular end-systolic diameter (LVESD): 59±6mm, Pulmonary 
Capillary Wedge Pressure (PCWP): 27±5 mmHg, Cardiac Index 
(CI): 1.7±0.4 liters/min/m2) who received LVAD. Four patients, 
suffering from end-stage ischemic cardiomyopathy underwent 
LVAD implantation as “destination therapy” and 4 patients with 
non-ischemic cardiomyopathy as bridge to transplantation or 
to “recovery” (“Harefield Athens Recovery Program”). All pa-
tients received an implantable axial flow, non-pulsatile Heart 
Mate II LVAS (Thoratec Corp; Pleasanton, CA). 
 
Clinical protocol 
All patients underwent serial evaluation with cardiopulmonary 
exercise test (CPET) and respiratory function tests after LVAD 
implantation.  
All patients after LVAD implantation were under optimal medi-
cal treatment. In patients with non-ischemic cardiomyopathy, 
clenbuterol (β2-agonist) was added to standard treatment 
when maximal regression of the LVEDD had plateaued.  
In the study we also included a control group of 8 patients (6 
males, 4 with ischemic and 4 with dilated cardiomyopathy, 
53±11years, BMI: 28±5kg/m2, EF: 28.5±5.8%) with advanced 
systolic HF, and a peak oxygen uptake ≤ 19ml/kg/min non-
treated with LVAD. These patients were randomly chosen from 
the population followed in our long-term heart failure pro-
gram. Informed consent was obtained from all patients, and 
the study was approved by the Human Studies Ethics Commit-
tee of our Institution.  
 
Respiratory function tests 
After familiarization of the patient with the laboratory envi-
ronment, measurements of forced vital capacity (FVC) and 
forced expiratory volume at 1 sec (FEV1) were performed in the 
sitting position with a closed-circuit spirometer (SensorMedics, 
Yorba Linda, CA). In all patients the maximal inspiratory pres-
sure (Pimax) was measured at rest, using a system for pulmonary 
tests as previously described.4 All tests were performed 1, 3 
and 6 months after LVAD implantation. 
Measurements of the mouth occlusion pressure (P0.1) were 
made 100ms after the onset of inspiration at rest. P0.1 is the 
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inspiratory pressure that develops in the first 100ms of an in-
spiratory effort against a closed valve, at the level of functional 
residual capacity, at rest. After 4 calm breaths with stable func-
tional residual capacity (FRC) the level of FRC was detected. 
Then the valve was randomly closed, to minimize the likelihood 
of a deliberate respiratory effort exerted by the patient against 
the valve. The measurement was repeated 6-8 times, and P0.1 
was calculated as the average of 4 measurements that differed 
by <5%.9 P0.1 was expressed as an absolute value (cmH2O), and 
as a percentage of Pimax (P0.1/ Pimax) to normalize its measure-
ment for individual differences in inspiratory muscle strength. 
 
Exercise test 
Each subject performed a symptom-limited ramp-incremental 
exercise test, so as to aim for a test of 8-12 min duration (work 
increments calculated as previously described9). The subjects 
breathed through a mouthpiece allowing pulmonary gas ex-
change and ventilatory variables to be obtained from gas ana-
lyzers and a mass flow sensor (Vmax 229; Sensormedics; Yorba 
Linda, CA). Mean inspiratory flow (VT/TI) and end-tidal carbon 
dioxide (PETCO2), minute ventilation (VE), tidal volume (VT), 
breathing frequency (fb), inspiratory time (TI), total respiratory 
time (TTot), and respiratory cycle (TI/TTot), were also calculated. 
 
Echocardiography 
Conventional transthoracic echocardiographic examination was 
performed in all patients in order to assess Left Ventricle (LV) 
internal dimensions and LVEF.  
 
Statistical analysis 
Continuous variables are presented as mean±Standard Devia-
tion. Group means of continuous variables were compared by 
unpaired Student’s t-test. Repeated measures of analysis of 
variance (ANOVA) and Bonferroni post hoc test of significance 
were used for the statistical evaluation of the within and be-
tween group differences during the follow-up period. Normali-
ty of distribution was assessed with the Shapiro-Wilk test. Cor-
relations between variables were obtained and tested by Pear-
son’s correlation coefficient after tested for normality curves.  
 
RESULTS 
All LVAD patients had impaired respiratory drive at initial eval-
uation which presented a trend towards normalization during 
the 6 month follow-up period. Specifically a decrease in P0.1 
and P0.1/Pimax%(Figure 1) as well as an increase in Pimax and VT at 
peak exercise was observed (Table 1). The patients in the con-
trol group had a statistically insignificant trend for a decrease 
in P0.1. 
A significant increase in exercise capacity was noted in all LVAD 
patients, expressed by VO2p and VO2AT, as previously de-
scribed.11 The Pimax increase after 6 months of follow-up was 
inversely correlated with the VO2p increase (r=-0.88; p<0.05). 
No deference in exercise capacity was observed in the control 
group. 
A significant decrease in LVEDD, LVESD and an improvement in 
LVEF is observed at 1, 3 and 6 months after LVAD implantation 
(Table 2).  
 
DISCUSSION  
The main findings of the study were that implantation of a con-
tinuous-flow LVAD in advanced HF patients progressively in-
duced a significant improvement in respiratory drive with par-
allel improvement in exercise capacity and LV systolic function 
and dimensions in the non-ischemic group.  
Previous studies have demonstrated a higher respiratory drive, 
reflected by resting P0.1 and P0.1/Pimax in patients with HF in 
comparison to healthy controls6,12 and that is associated with 
HF severity8. An excessive activation of the ergoreceptors has 
been reported in these patients, along with cachexia, autonom-
ic abnormalities and elevated plasma catecholamines concen-
trations.13 The heightened sympathetic activation, vasoconstric-
tor response and ventilatory drive might be partially explained 
by the exaggerated ergoreflexes during exercise.   
It is possible that LVAD implantation, reversing the chronic 
stressor state and the ensuing neurohormonal activation, can 
induce similar changes in skeletal muscles. We have previously 
shown that LVAD induces a progressive improvement in respir-
atory skeletal muscle dysfunction.11 Though, the enhanced 
ergoreflex of HF patients could be brought to levels closer to 
normalization after LVAD, possibly inducing changes to res-
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piratory drive similar to those observed after exercise rehabili-
tation.9  
Autonomous nervous system is severely deranged immediately 
after LVAD implantation and these abnormalities persist 3 
months after LVAD implantation with a tendency to improve.14 
The autonomic derangement being restored after LVAD im-
plantation through unloading of the failing heart, may contrib-
ute to respiratory drive restoration up to a point 15,16 improving 
the adrenergic pathways and the sympathetic innervation. 
Previous studies have shown a significant reverse remodeling 
of the failing myocardium, as well as, a hemodynamic im-
provement after LVAD implantation.17-19 Our study results are 
consistent with those of previous studies in patients with non-
ischemic HF.  
Interestingly, in our study a significant inverse correlation of 
the percentage changes of Pimax and VO2p was evident after six 
months of LVAD support mainly evidenced in non-ischemic 
LVAD patients. An explanation of these findings may be the 
additional effect of clenbuterol in these patients comparing to 
ischemic LVAD patients and its greater effect on the peripheral 
muscles strength, with ‘less positive’ effects to muscle oxidative 
capacity.  
Limitations 
The small number of patients and the short follow up period 
are the main limitations of our study. We also included patients 
with ischemic and non-ischemic HF patients, although the 
sample size was small for separate analysis according to HF 
etiology. Finally the use of clenbuterol might interpret along-
side with LVAD implantation. 
 
CONCLUSIONS  
Concluding, with this study we demonstrate that a continuous-
flow LVAD induces a progressive and significant improvement 
of respiratory drive and Left ventricle reverse remodeling dur-
ing a 6 month follow-up period. 
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ANNEX 
TABLE 1. Respiratory drive, respiratory function and CPET parameters in LVAD patients 
  Post LVAD  
1 month 
Post LVAD 
 3 months 
Post LVAD 
 6 months 
 
Respiratory drive parameters   
P0.1, cmH2O 2.61±0.58 2.44±0.42 2.34±0.44 
P0.1/Pimax % 4.17±0.43 3.29±1.0 2.56±0.35† 
Pimax, cmH2O 63±16 78±17 93±20† 
VTbase, L 0.5±0.07 0.5±0.1 0.6±0.1 
VTpeak, L 1.18±0.21 1.29±0.29 1.51±0.33† 
VT/TIbase, L/min 26.8±9.6 22.5±6.8 30.1±8 
VT/TIpeak,L/min 116.2±30.4 103.8±21.4 129.3±23.2* 
PETCO2base,mmHg 32.7±6.3 36.7±4.8 30.7±2.6* 
PETCO2peak, mmHg 26.7±6.8 31.6±6.7 26.1±3.9* 
fbbase, bpm 23.8±3.8 22.2±2.1 22.5±3.7 
fbpeak,bpm 48.8±10.6 40.2±5.9 43.3±6* 
 
Respiratory function parameters 
FEV1,(L) 1.97±0.29 2.22±0.45 2.4±0.49* 
FEV1,(%predicted) 59±7 66±12 71±13* 
FVC,(L) 2.33±0.45 2.8±0.66 3.1±0.75* 
FVC,(%predicted) 53±11 67±13 74±15* 
FEV1/FVC,(%) 86±11 80±7 79±9* 
    
CPET parameters 
VO2p, L/min 0.78±0.08 0.87±0.17 1.1±0.14† 
VO2p, ml/kg/min 12.5±1.3 13±1.5 14.9±1.6* 
VO2AT, ml/kg/min 7.7±0.75 9±0.8 10.9±1.7* 
VO2 (% predicted) 39.28±1.88 42.0±7.07 48.14±4.22† 
VE/VCO2 slope 41.8±13.3 33.7±6.3 37.6±3.5 
ExerciseTime(min) 5±1.7 6.5±1.7 8.5±1.1* 
RER 1.4±0.18 1.3±0.21 1.2±0.07 
VD/VT at peak 0,3±0,04 0.28±0,05 0.25±0.05* 
HR rest 91±8 75±21 76±14 
HR peak  131±15 120±41 124±25 
HR recovery 22±14 14±15 20±10 
Data are expressed as mean±standard deviation. Baseline for the LVAD group was 1 month after implantation. 
P0.1=mouth occlusion pressure 100 ms after the onset of inspiration, P0.1/Pimax=mouth occlusion pressure/max inspiratory pressure, Pi-
max=Maximum inspiratory pressure, VTbase=Tidal volume at baseline, VTpeak= Tidal volume at peak exercise, VT/TIbase=mean inspiratory 
flow at baseline, VT/TIpeak= mean inspiratory flow at peak exercise, PETCO2base=end-expiratory CO2 at baseline, PETCO2peak=end-
expiratory CO2 at peak exercise, fbbase=breathing frequency at baseline, fbpeak=breathing frequency at peak exercise, FEV1=Forced ex-
pired volume in 1 sec, FVC=forced vital capacity, VO2p=Peak oxygen uptake, VO2AT=Anaerobic threshold, VE=Minute ventilation. 
VE/VCO2 slope=the slope of ventilatory equivalent for carbon dioxide output, RER=Respiratory exchange ratio, VD/VT at peak =the ratio 
of physiologic dead space over tidal volume  
 
†p<0.01 vs baseline, *p<0.05 vs baseline. 
 
 
TABLE 2. Echocardiographic measurements at rest, before and after LVAD implantation 
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Data expressed as mean±standard deviation. LVEDD=Left ventricular end-diastolic diameter, LVESD=Left ventricular end-systolic di-
ameter, LVEF=Left ventricular ejection fraction 
*p<0.05 vs baseline, †p<0.01 vs baseline 
 
FIGURE 1. Error bar of P0.1/Pimax % at 1, 3 and 6 months post LVAD implantation 
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